News

LynFit Nutrition is a recurring segment featured on“CT BUZZ,” where Metabolic Weight Loss & Fat Burning Expert, Lisa Lynn, ...
Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...
"Nordic Cold Chain launches cold chain packaging for GLP-1 drugs" was originally created and published by Packaging Gateway, ...
CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...
Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...
This is only a glimpse of the data available to CivicScience clients. Discover more data. It’s safe to say that GLP-1 ...
GLP-1 drugs alter taste perceptions, challenging food makers to adapt by enhancing umami flavours, balancing sweetness, and ...
Here’s a roundup of numbers from the last week of HR news — including the percentage of managers who use AI to help determine ...
GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...
GLP-1 drugs like Ozempic® and Zepbound® have gained significant attention for treating both diabetes and assisting with weight loss.
Changes in eating habits are impacting some categories, like snacks, more than others. Taking GLP-1 drugs reduces a person's appetite significantly, slowing down the emptying of the stomach and making ...
GLP-1 weight loss patches are everywhere but do they actually work as these trendy patches promise Ozempic-like results ...